Gemini cuts workforce ~80%, initiates strategic review; CEO departs

Disc Medicine, Inc.

Workforce reduction of 24 employees (approx. 80%) by end of Q2 2022; restructuring charge $1.6-1.9M in Q1 2022.
CEO Jason Meyenburg departs; Executive Chair Georges Gemayel appointed interim President and CEO.
Company initiates strategic alternatives review to maximize shareholder value; no timetable set.
Remaining employees to focus on GEM307 IND-enabling tasks.
Separation agreement includes 12 months base salary, pro-rata bonus, COBRA, and continued equity vesting.

item 2.05 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jason Meyenburg

President and Chief Executive Officer

IRON · Disc Medicine, Inc.

Effective: 2022-02-28
Successor: Georges Gemayel
Filed: February 28, 2022, 6:59 PM ET

Mr. Meyenburg’s last date of employment with the Company as its President and Chief Executive Officer is February 28, 2022

Appointed (interim)

Georges Gemayel

Interim President and Chief Executive Officer

IRON · Disc Medicine, Inc.

Effective: 2022-02-28
Filed: February 28, 2022, 6:59 PM ET

the Board appointed Dr. Georges Gemayel, the Company’s current Executive Chair, to serve as Interim President and Chief Executive Officer, effective as of February 28, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason Meyenburg resigned as President and Chief Executive Officer at Disc Medicine, Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

Mr. Meyenburg’s last date of employment with the Company as its President and Chief Executive Officer is February 28, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Georges Gemayel was appointed as Interim President and Chief Executive Officer at Disc Medicine, Inc..

Action: appointed
Role: Interim President and Chief Executive Officer

Exact text from the filing

the Board appointed Dr. Georges Gemayel, the Company’s current Executive Chair, to serve as Interim President and Chief Executive Officer, effective as of February 28, 2022.

View on SEC.gov

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-055899

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.